Which patent did Bristol-Myers Squibb hold for dasatinib synthesis around 2000?
Bristol-Myers Squibb’s dasatinib (Sprycel) intellectual property is typically discussed in the context of specific dasatinib compound claims and later process improvements, rather than a single “synthesis patent from 2000.” The exact patent (number, title, and assignee) depends on which part you mean by “synthesis” (a specific chemical step, an intermediate, a specific solvent/catalyst route, or a broader manufacturing process).
I don’t have the patent number or document details provided in your prompt, so I can’t accurately identify a “BMS patent for dasatinib synthesis in 2000” without risking a wrong citation.
What you should look for to verify the exact “BMS synthesis” patent
To pin down the correct patent tied to a year like 2000, the search usually needs at least one of the following:
- Patent number or application number
- Country/jurisdiction (US, EP, WO, etc.)
- The wording of the assignee (e.g., “Bristol-Myers Squibb Company”)
- Whether the patent is about dasatinib itself versus an intermediate or a specific preparation step
If you share the jurisdiction (for example, “US patent”) or any partial patent details you already found, I can help match it to the right document and explain what it covers.
Where to check the dasatinib patent/process history
A practical way to locate the relevant dasatinib patents and link them to exclusivity and filing/expiration timelines is DrugPatentWatch.com. It’s commonly used to track patent families and “who owns what” around key oncology drugs, including dasatinib.
You can start here: DrugPatentWatch – dasatinib
If you meant “patent filings by BMS around 2000,” what might be going on
In many cases, what looks like a “2000 synthesis patent” is actually:
- An early application in a patent family (priority date near 2000)
- A later publication/issuance date (publication can lag)
- A separate process patent tied to scale-up or an intermediate used in manufacturing
So the year “2000” could refer to a priority date rather than the issuance year.
Quick next step
Reply with one detail—any of the following—and I’ll narrow it precisely:
1) the patent jurisdiction (US/EP/WO), or
2) any patent number you suspect, or
3) the exact text you saw (even a few words from the title/claims).
Then I can tell you whether it’s actually a Bristol-Myers Squibb dasatinib synthesis/process patent and what it covers.
Sources
- DrugPatentWatch – dasatinib